You are here: Home » Companies » News
Business Standard

Torrent Pharma, Reliance Life sign licensing agreement for biosimilars

The licensing agreement is expected to significantly boost presence in oncology and dermatology segments

BS Reporter  |  Mumbai 

The Ahmedabad-based has entered into an exclusive licensing agreement with for marketing three in India — Rituximab, and

and cater to the oncology segment and are used in the treatment of various cancers such as leukaemia, lymphoma, colorectal, head and neck. is the therapy for the treatment of auto-immune disorders such as rheumatoid arthritis, psoriasis and inflammatory bowel disease. According to the terms of the agreement, will manufacture these products at its facility in Navi Mumbai and supply to Torrent Pharma for a period of 10 years, after obtaining all necessary regulatory approvals.

Torrent had launched exclusive divisions for oncology and dermatology segments in 2011-12. The licensing agreement with is expected to significantly boost its presence in these segments in the coming years, said a statement from Torrent.

First Published: Fri, December 26 2014. 00:20 IST